Blog Posts
March 15, 2021

Overcoming the Void of In-Person KOL Engagements

Blog Posts
March 15, 2021

Overcoming the Void of In-Person KOL Engagements

Author

Building rapport and relationships is different in virtual realm, but still a crucial part of the human experience and the role of the MSL. Acknowledging this void and being comfortable with technology platforms, flexible and efficient are some of the key messages that emerged out of the MSL  Society's webinar.

On March 10, 2021, the MSL Society hosted a live webinar to discuss the experience of MSL leaders and teams nearly a year to the day since the COVID-19 pandemic shut down their ability to meet with KOLs in person in much of the world.

The conversation was moderated by MSL Society SEO, Dr. Samuel Dyer, and included MSL leaders Julio Fernandez (Novartis Oncology) and Dr. Niccole Larsen (ACADIA Pharmaceuticals) along with LARVOL CEO Bruno Larvol.  

The panelists’ shared about both the challenges and opportunities that have emerged in this unique time, and offered advice to MSLs hoping to strengthen their KOL engagements this year. Read on for highlights and a short snippet from the hour-long conversation, provided by the MSL Society.

The panelists spoke to the utilization of technology as the biggest factor in overcoming the void of in-person KOL engagements.

Julio encouraged MSLs to investigate and be comfortable with a number of technology platforms so that they can meet KOLs on the platforms that are convenient for them and, importantly, allowed by their institutions. Niccole recommended asynchronous learning platforms as an emerging technology that can allow MSLs to manage education of groups in a virtual space.  

They also emphasized that MSLs need to remain flexible and to focus on efficiency. They can play an important role in helping to connect HCPs with various people throughout their organization if they can truly understand the needs of the KOLs.

Bruno recognized that this ‘void’ of face-to-face engagements is new to the MSL experience and is very real and important. Building rapport and relationships is different in virtual realm, but still a crucial part of the human experience and the role of the MSL.  

To the question of how to establish relationships with new KOLs without in-person engagements, the panelists emphasized networking and leveraging existing resources as key.

Julio recommended using both the MSL’s internal network and the KOLs they engage with already to look for connections that might lead to an introduction. He emphasized, however, that the MSL must bring value to each of these relationships in order to establish and maintain them.  

“You have to earn the right for the next meeting by providing value” he shared. And Niccole agreed, emphasizing the need to make meetings more planned-out, even “regimented” to ensure their value.  

“KOLs expect to stay on schedule since they are pulled in multiple directions and have limited time for scientific exchange.” It’s really important to be respectful of their time.  

Bruno added that MSLs might carefully consider social media in this equation. “Active listening in social media is essential to gradually build that relationship” with new and existing KOLs as they increasingly engage in scientific conversation online.

Discover more insights in our infographic and download this pdf for the full report.

LARVOL OMNI is a KOL Monitoring & Engagement solution that helps you stay up-to-date with all aspects of your KOL activity. Request a product walkthrough today!

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.